Subtype analysis and mutations to antiviral drugs in HIV‐1‐infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme
- 23 June 2005
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 76 (4) , 452-458
- https://doi.org/10.1002/jmv.20382
Abstract
Phylogenetic analysis and evaluation of drug‐resistance were carried out upon 59 plasma samples from 58 treatment‐naïve HIV‐1 infected patients from Mozambique, enrolled in a free antiviral‐therapy protocol in the frame of Drug‐Resource‐Enhancement against AIDS and Malnutrition (DREAM) programme. Sequencing of the first 1,300 bases of the pol‐gene shows that all virus strains cluster within clade C, with the exception of a single patient carrying a G‐subtype virus. Relevant mutations in the reverse transcriptase (RT) are rare: 118A/I/L/G (four patients), 179E/D/I (three patients), 333E/D (two patients), 101R, and 210F (one patient each). In Protease (PR), V82I (10.3%) is the only relevant mutation, while natural polymorphisms/secondary mutations are found, some at very high frequency: 20R (25.9%), 36I (91.4%), 36L (8.6%), 60E (31.0%), 63P (29.3%), and 93L (96.6%). Among them, mutations with a frequency >25% were further investigated to assess their covariation pattern with PI resistance associated mutations. The pattern of covariation observed for K20R and D60E (but not L63P and M36I) was different between C and B subtype isolates from PR‐inhibitor‐treated patients. The sequences were also analyzed to calculate the ratio of non‐synonymous to synonymous substitution. The ratio for PR and RT was 0.116 and 0.093, respectively, suggesting a greater conservation in RT than PR in both subtypes B and C HIV strains. Taken together, the results demonstrate a consistent clade‐homogeneity of viral strains circulating in Mozambique, and the very limited presence, in drug‐naïve patients, of mutations associated with resistance to RT‐inhibitors. The high frequency of secondary mutations/polymorphisms in HIV‐PR deserves further studies to evaluate its relevance in clinical settings. J. Med. Virol. 76:452–458, 2005.Keywords
This publication has 19 references indexed in Scilit:
- Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypesJournal of Clinical Virology, 2004
- Minor Mutations in HIV Protease at Baseline and Appearance of Primary Mutation 90M in Patients for Whom Their First Protease‐Inhibitor Antiretroviral Regimens FailedThe Journal of Infectious Diseases, 2004
- Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug‐Naive Patients Treated with Protease Inhibitor–Based TherapyThe Journal of Infectious Diseases, 2001
- Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypesProceedings of the National Academy of Sciences, 2001
- Use of Drug Resistance Sequence Data for the Systematic Detection of Non?B Human Immunodeficiency Virus Type 1 (HIV?1) Subtypes: How to Create a Sentinel Site for Monitoring the Genetic Diversity of HIV?1 at a Country ScaleThe Journal of Infectious Diseases, 2001
- Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?The Lancet, 2000
- Sequence Note: Genetic Characterization and Phylogenetic Analysis of HIV-1 Subtype C from UgandaAIDS Research and Human Retroviruses, 2000
- HIV-1 Nomenclature ProposalScience, 2000
- Sequence Note: Variation in HIV Type 1 V3 Region env Sequences from MozambiqueAIDS Research and Human Retroviruses, 1998
- Genetic Characterization of HIV Type 1 from Migrant Workers in Three South African Gold MinesAIDS Research and Human Retroviruses, 1998